Listed here, we explain a pharmacogenetics tactic that permits to selectively and reversibly inactivate LC neurons applying Designer Receptors Exclusively Activated by Designer Medicines (DREADD). We display the expression on the hM4Di DREADD may be limited to noradrenergic LC neurons and that the amount of LC inhibition could be modified by adapti